Your browser is no longer supported. Please, upgrade your browser.
Settings
NRIX [NASD]
Nurix Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own2.55% Shs Outstand44.37M Perf Week-2.71%
Market Cap1.23B Forward P/E- EPS next Y-3.09 Insider Trans-3.32% Shs Float43.30M Perf Month-19.28%
Income-89.10M PEG- EPS next Q-0.69 Inst Own91.70% Short Float7.13% Perf Quarter-4.62%
Sales22.90M P/S53.80 EPS this Y41.70% Inst Trans1.54% Short Ratio9.09 Perf Half Y-17.28%
Book/sh8.46 P/B3.32 EPS next Y-14.00% ROA-22.00% Target Price49.17 Perf Year3.74%
Cash/sh7.83 P/C3.58 EPS next 5Y- ROE-29.80% 52W Range21.53 - 52.38 Perf YTD-14.69%
Dividend- P/FCF- EPS past 5Y- ROI-15.30% 52W High-46.45% Beta-
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low30.28% ATR1.66
Employees135 Current Ratio7.10 Sales Q/Q151.20% Oper. Margin- RSI (14)39.43 Volatility4.11% 5.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.10% Profit Margin- Rel Volume0.51 Prev Close28.16
ShortableYes LT Debt/Eq0.00 EarningsJul 13 AMC Payout- Avg Volume339.60K Price28.05
Recom1.70 SMA20-5.76% SMA50-11.75% SMA200-13.34% Volume173,627 Change-0.39%
Oct-14-21Initiated SVB Leerink Outperform $50
Jun-04-21Resumed Robert W. Baird Outperform $45 → $46
Apr-30-21Resumed Piper Sandler Overweight $60
Apr-30-21Initiated RBC Capital Mkts Outperform $42
Apr-14-21Initiated Berenberg Buy
Nov-19-20Initiated Robert W. Baird Outperform $40
Aug-18-20Initiated Stifel Buy $34
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-18-20Initiated Needham Buy $35
Aug-18-20Initiated JP Morgan Overweight $35
Oct-21-21 07:00AM  
Oct-14-21 05:15PM  
04:02PM  
Sep-30-21 07:00AM  
Jul-27-21 07:00PM  
Jul-26-21 07:25AM  
Jul-13-21 04:01PM  
Jun-21-21 04:01PM  
Jun-02-21 07:00AM  
Jun-01-21 04:00PM  
May-21-21 07:00AM  
May-11-21 07:00AM  
Apr-18-21 03:51AM  
Apr-13-21 04:01PM  
Apr-07-21 07:00AM  
Mar-16-21 09:31AM  
Mar-10-21 05:12PM  
Mar-09-21 04:01PM  
07:30AM  
Mar-04-21 08:01PM  
Mar-02-21 04:15PM  
Feb-21-21 03:24AM  
Feb-18-21 12:07AM  
Feb-17-21 06:20AM  
Feb-16-21 04:01PM  
Jan-07-21 07:00AM  
Jan-05-21 07:00AM  
Dec-12-20 03:39PM  
Dec-07-20 10:01AM  
Nov-09-20 07:00AM  
Nov-04-20 04:01PM  
Oct-26-20 01:09PM  
08:00AM  
Oct-14-20 04:05PM  
Oct-06-20 08:00AM  
Jul-24-20 01:07PM  
Jul-23-20 06:25PM  
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ring ChristineGeneral CounselOct 11Option Exercise1.861,2002,2322,486Oct 12 06:43 PM
Ring ChristineGeneral CounselOct 11Sale27.361,20032,8321,286Oct 12 06:43 PM
Hansen GwennChief Scientific OfficerOct 01Option Exercise7.264002,90414,597Oct 04 05:16 PM
Hansen GwennChief Scientific OfficerOct 01Sale29.9240011,96814,197Oct 04 05:16 PM
Ring ChristineGeneral CounselSep 10Option Exercise1.862,0003,7203,286Sep 13 04:07 PM
Ring ChristineGeneral CounselSep 10Sale35.932,00071,8601,286Sep 13 04:07 PM
Hansen GwennChief Scientific OfficerSep 07Option Exercise7.261,60011,61615,797Sep 08 05:08 PM
Ring ChristineGeneral CounselSep 07Option Exercise1.863,2005,9524,486Sep 08 05:08 PM
Ring ChristineGeneral CounselSep 07Sale35.253,200112,8001,286Sep 08 05:08 PM
Hansen GwennChief Scientific OfficerSep 07Sale35.001,60056,00014,197Sep 08 05:08 PM
Hansen GwennChief Scientific OfficerSep 01Option Exercise7.264002,90414,597Sep 02 04:22 PM
Hansen GwennChief Scientific OfficerSep 01Sale32.3440012,93614,197Sep 02 04:22 PM
Beaurang PierreChief Business OfficerAug 10Option Exercise1.117,5008,32511,830Aug 11 06:20 PM
Ring ChristineGeneral CounselAug 10Option Exercise1.861,2002,2322,005Aug 11 06:21 PM
Beaurang PierreChief Business OfficerAug 10Sale29.867,500223,9264,330Aug 11 06:20 PM
Ring ChristineGeneral CounselAug 10Sale29.871,20035,845805Aug 11 06:21 PM
Hansen GwennChief Scientific OfficerAug 02Option Exercise7.264002,90414,204Aug 03 05:39 PM
Hansen GwennChief Scientific OfficerAug 02Sale31.2140012,48413,804Aug 03 05:39 PM
Ring ChristineGeneral CounselJul 20Option Exercise1.861,2002,2322,005Jul 21 05:34 PM
Ring ChristineGeneral CounselJul 20Sale27.001,20032,400805Jul 21 05:34 PM
Beaurang PierreChief Business OfficerJul 12Option Exercise1.117,5008,32511,830Jul 12 07:36 PM
Beaurang PierreChief Business OfficerJul 12Sale23.927,500179,4194,330Jul 12 07:36 PM
Beaurang PierreChief Business OfficerJun 10Option Exercise1.117,5008,32511,830Jun 11 04:10 PM
Ring ChristineGeneral CounselJun 10Option Exercise1.861,2002,2322,005Jun 11 04:11 PM
Ring ChristineGeneral CounselJun 10Sale29.401,20035,282805Jun 11 04:11 PM
Beaurang PierreChief Business OfficerJun 10Sale29.377,500220,2484,330Jun 11 04:10 PM
Hansen GwennChief Scientific OfficerJun 01Option Exercise7.264002,90414,204Jun 02 04:49 PM
Hansen GwennChief Scientific OfficerJun 01Sale27.7440011,09613,804Jun 02 04:49 PM
Ring ChristineGeneral CounselMay 10Option Exercise1.861,2002,2322,005May 11 07:58 PM
Ring ChristineGeneral CounselMay 10Sale27.001,20032,400805May 11 07:58 PM
Hansen GwennChief Scientific OfficerMay 03Option Exercise7.268005,80814,604May 04 04:27 PM
Hansen GwennChief Scientific OfficerMay 03Sale34.9980027,99613,804May 04 04:27 PM
Ring ChristineGeneral CounselApr 28Option Exercise1.868001,4881,605Apr 29 06:05 PM
Ring ChristineGeneral CounselApr 28Sale35.2580028,200805Apr 29 06:05 PM
Ring ChristineGeneral CounselApr 12Option Exercise1.861,2002,2322,005Apr 13 05:20 PM
Ring ChristineGeneral CounselApr 12Sale27.201,20032,640805Apr 13 05:20 PM
Hansen GwennChief Scientific OfficerApr 05Option Exercise7.264002,90414,204Apr 06 04:04 PM
Hansen GwennChief Scientific OfficerApr 05Sale35.0040014,00013,804Apr 06 04:04 PM
Hansen GwennChief Scientific OfficerApr 01Option Exercise7.264002,90414,204Apr 02 05:22 PM
Hansen GwennChief Scientific OfficerApr 01Sale31.5540012,62013,804Apr 02 05:22 PM
Beaurang PierreChief Business OfficerMar 25Option Exercise0.844,3303,6374,330Mar 25 07:23 PM
Hansen GwennChief Scientific OfficerMar 16Option Exercise7.268005,80814,604Mar 16 06:50 PM
Hansen GwennChief Scientific OfficerMar 16Sale45.0080036,00013,804Mar 16 06:50 PM
Ring ChristineGeneral CounselMar 10Option Exercise1.862,0003,7202,805Mar 11 05:35 PM
Ring ChristineGeneral CounselMar 10Sale41.272,00082,539805Mar 11 05:35 PM
Beaurang PierreChief Business OfficerMar 08Option Exercise0.847,5006,3007,500Mar 09 04:04 PM
Beaurang PierreChief Business OfficerMar 08Sale37.027,500277,6780Mar 09 04:04 PM
Hansen GwennChief Scientific OfficerMar 01Option Exercise7.268005,80814,604Mar 02 05:29 PM
Hansen GwennChief Scientific OfficerMar 01Sale35.9580028,76013,804Mar 02 05:29 PM
van Houte HansChief Financial OfficerFeb 24Option Exercise1.7635,41962,29735,419Feb 25 04:18 PM
van Houte HansChief Financial OfficerFeb 24Sale39.9035,4191,413,2180Feb 25 04:18 PM
van Houte HansChief Financial OfficerFeb 22Option Exercise1.105,3305,8865,330Feb 23 06:04 PM
van Houte HansChief Financial OfficerFeb 22Sale39.935,330212,8390Feb 23 06:04 PM
Beaurang PierreChief Business OfficerFeb 18Option Exercise3.6815,00055,27515,000Feb 22 04:06 PM
Hansen GwennChief Scientific OfficerFeb 18Option Exercise7.268005,80812,800Feb 22 04:07 PM
Ring ChristineGeneral CounselFeb 18Option Exercise1.862,0003,7202,000Feb 22 04:08 PM
van Houte HansChief Financial OfficerFeb 18Option Exercise0.8413,58311,41013,583Feb 22 04:09 PM
van Houte HansChief Financial OfficerFeb 18Sale35.4613,583481,6210Feb 22 04:09 PM
Ring ChristineGeneral CounselFeb 18Sale35.882,00071,7500Feb 22 04:08 PM
Hansen GwennChief Scientific OfficerFeb 18Sale36.2780029,01812,000Feb 22 04:07 PM
Beaurang PierreChief Business OfficerFeb 18Sale35.4915,000532,3520Feb 22 04:06 PM
Hansen GwennChief Scientific OfficerNov 30Option Exercise0.8412,00010,08012,000Dec 01 09:32 PM